Business Context and Reporting Period
Company: Leucadia National Corporation (Note: The filing text identifies the registrant as Leucadia National Corporation, despite the user metadata referencing Jefferies Financial Group. Leucadia is a diversified holding company with significant investments in Jefferies Group, Inc. and AmeriCredit Corp.)
Reporting Period: Fiscal year ended December 31, 2008.
Business Overview: Leucadia operates as a diversified holding company with segments in manufacturing (Idaho Timber, Conwed Plastics), telecommunications (STi Prepaid), property management (ResortQuest), gaming entertainment (Premier/Hard Rock Biloxi), domestic real estate, medical product development (Sangart), and wineries. The company also holds significant non-controlling investments in associated companies, including Jefferies Group, Inc. (approx. 30%) and AmeriCredit Corp. (approx. 25%), which are accounted for at fair value.
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Total Revenues and Other Income | $1,080.7 million | $1,154.9 million |
| Net Income (Loss) | $(2,535.4 million) | $484.3 million |
| Income (Loss) from Continuing Operations | $(2,579.3 million) | $480.8 million |
| Income (Loss) Before Taxes (Continuing Ops) | $(366.6 million) | $(57.1 million) |
| Income (Loss) Related to Associated Companies | $(539.1 million) | $(21.9 million) |
| Total Assets | $5,198.5 million | $8,126.6 million |
| Total Debt (Current + Long-term) | $2,081.5 million | $2,136.6 million |
| Shareholders' Equity | $2,676.8 million | $5,570.5 million |
| Book Value Per Share | $11.22 | $25.03 |
| Cash and Cash Equivalents | $237.5 million | $457.0 million |
| Net Cash Provided by Operating Activities | $8.8 million | $(18.4 million) |
Material Changes vs. Prior Period
- Net Loss: The company reported a net loss of $2.54 billion in 2008, a significant reversal from a net income of $484 million in 2007.
- Deferred Tax Valuation Allowance: The primary driver of the loss was a $1.67 billion charge to income tax expense to establish a valuation allowance against substantially all of the company's net deferred tax asset ($2.35 billion), due to uncertainty regarding future taxable income.
- Investment Impairments and Unrealized Losses:
- Associated Companies: Unrealized losses of $155.3 million on AmeriCredit Corp. (ACF) and $111.2 million on Jefferies Group, Inc. were recognized in operations due to the election of the fair value option.
- Securities: Net securities losses totaled $144.5 million, including $143.4 million in impairment charges for declines in fair value deemed other than temporary.
- Other Comprehensive Loss: The investment in Fortescue Metals Group Ltd. declined in value by $921 million (reflected in equity, not operations).
- Segment Performance:
- Manufacturing: Idaho Timber revenues declined 19% to $235.3 million due to weak housing demand; Conwed Plastics revenues remained flat at $106.0 million.
- Telecommunications: STi Prepaid revenues increased 25% to $452.4 million, driven by acquisitions and carrier wholesale growth, though pre-tax income declined.
- Medical Product Development: Sangart reported a pre-tax loss of $32.3 million, reflecting continued R&D costs for Hemospan(R).
Guidance, Outlook, and Risks
- Outlook: Management expects the worldwide recession and credit market turmoil to continue, creating investment opportunities but making financing difficult. The company intends to pursue compelling opportunities using available liquidity or by disposing of existing assets.
- Subsequent Events (Post-Dec 31, 2008):
- Investment values in ACF and Jefferies continued to decline as of February 20, 2009. If values remain unchanged at March 31, 2009, an additional aggregate unrealized loss of $276.5 million would be recognized in Q1 2009.
- ACF failed to maintain a financial covenant in one credit facility and is negotiating amendments.
- Key Risks:
- Market Volatility: Significant exposure to declines in public securities markets, particularly affecting investments in Jefferies, ACF, Fortescue, and Inmet.
- Real Estate: Downturns in the U.S. housing market continue to adversely affect manufacturing (Idaho Timber), property management (ResortQuest), and real estate development segments.
- Regulatory and Clinical: Sangart's success depends on regulatory approval for Hemospan(R); Phase III trials did not demonstrate clinical benefit in the tested population, requiring further trials.
- Liquidity: While the company has $1.1 billion in available liquidity, access to capital markets for new investments may be constrained or costly.
Investor Verification Checklist
- Deferred Tax Asset Realizability: Verify the assumptions used to determine the $1.67 billion valuation allowance and the likelihood of future taxable income to reverse it.
- Investment Valuations: Monitor the fair value of the Jefferies and ACF investments, as further declines will directly impact earnings due to the fair value option election.
- ACF Covenant Compliance: Track the outcome of AmeriCredit Corp.'s negotiations with credit providers regarding the covenant waiver.
- Sangart Clinical Trials: Review the design and timeline of the new Phase II/III trials for Hemospan(R) to assess the path to revenue generation.
- Real Estate Exposure: Assess the impact of the prolonged housing recession on the valuation of the company's domestic real estate projects and the Myrtle Beach development.
- Liquidity Position: Confirm the availability of the $1.1 billion in liquid assets and the status of the $100 million unsecured bank credit facility.